1. Adapted from Catley et al, Pharm Therap 2011
Anti-IL-5
Anti-IL-13
Anti-IL-4
Anti-TNF
A number of monoclonal antibodies have been used in animal models and human eosinophilic disorders to target eosinophilic inflammation including anti-IL-5 (asthma, eosinophilic esophagitis, hypereosinophilic syndrome, nasal polyposis), anti-IL-13 (eosinophilic esophagitis, asthma), anti-TNF-alpha (asthma, eosinophilic esophagitis), anti-siglec-F (eosinophilia, eosinophilic esophagitis, eosinophilic gastroenteritis), and anti-IgE (asthma, eosinophilic esophagitis)
Anti-IgE
Anti-Siglec-F
Adapted from Catley et al, Pharm Therap 2011

2. Selected Reviews List
Catley et al, Monoclonal antibodies for the treatment of asthma, Pharmacology & Therapeutics 2011
Busse et al, A review of treatment with mepolizumab, an anti-IL-5 mAb in hypereosinophilic syndromes and asthma, JACI 2011
Stone and Prussin. Immunomodulatory therpy oeosinophili assoicate gastrointestinal diseases. Clin Exp Allergy, 2008